News Agency
Men's Weekly

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

  • Written by PR Newswire

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023

--Phase I clinical trial will also determine if ASC11 needs to be boosted by ritonavir or not

--In antiviral cellular assays,...

Read more: Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion